⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821600 | 1.00 | — | — | |
| SCHEMBL6361486 | 0.83 | ALDH1A1 (0.46) | — | |
| SCHEMBL15508350 | 0.81 | — | — | |
| SCHEMBL14427518 | 0.81 | — | — | |
| SCHEMBL307216 | 0.81 | — | — | |
| SCHEMBL875553 | 0.80 | — | — | |
| SCHEMBL7604693 | 0.80 | — | — | |
| SCHEMBL5141952 | 0.78 | — | — | |
| SCHEMBL5141953 | 0.78 | — | — | |
| SCHEMBL941953 | 0.78 | LMNA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |